Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Genmab
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
iOnctura
Merck Sharp & Dohme LLC
Pfizer
City of Hope Medical Center
AstraZeneca
HonorHealth Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
University of Southern California
National Cancer Institute (NCI)
University of Vermont
Tesaro, Inc.
AbbVie
Memorial Sloan Kettering Cancer Center
Toray Industries, Inc
Dana-Farber Cancer Institute
Daiichi Sankyo
University Hospital, Geneva
University College, London